日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study

帕博利珠单抗、乐伐替尼和减量吉西他滨/奥沙利铂作为晚期胆道癌一线治疗的疗效和安全性：一项多中心、单臂、前瞻性 II 期研究

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-014653
Piao, Mingjian; Li, Chengjie; Li, Shuofeng; Zhang, Nan; Li, Jiongyuan; Luo, Xu; Liu, Rong; Wang, Fei; Shi, Xiangde; Liu, Chao; Tan, Guang; Zhu, Zhenyu; Yang, Xiaobo; Zhao, Haitao
肿瘤
胆管癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability/mismatch repair-deficient advanced cholangiocarcinoma: A propensity score-matched study

免疫检查点抑制剂治疗高微卫星不稳定性/错配修复缺陷型晚期胆管癌患者的疗效和安全性：一项倾向评分匹配研究

期刊:Jhep Reports
影响因子:7.5
doi:10.1016/j.jhepr.2026.101816
Piao, Mingjian; Yang, Xu; Li, Chengjie; Zhao, Jiayi; Zhang, Nan; Li, Jiongyuan; Huang, Ziyue; Li, Shuofeng; Sun, Boyu; Yang, Xiaobo; Zhao, Haitao
肿瘤
胆管癌
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study

局部区域治疗联合免疫检查点抑制剂、化疗和乐伐替尼与免疫检查点抑制剂联合化疗治疗晚期肝内胆管癌的疗效比较：一项多中心研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04259-x
Wang, Mingming; Li, Shuofeng; Yu, Guanhua; Zhang, An; Ding, Shikang; Zhang, Yihong; Feng, Shi; Zhou, Zixiang; Piao, Mingjian; Pan, Weixuan; Li, Chengjie; Sun, Boyu; Li, Jiongyuan; Zhang, Nan; Chen, Xinyuan; Sun, Yongliang; Zhang, Wen; Zhu, Zhenyu; Zhao, Haitao
肿瘤
胆管癌
肿瘤免疫
免疫/内分泌
发表日期：2026
文献求助 收藏

Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception

胰腺腺鳞癌鳞状细胞转化过程中免疫监视功能的减弱，为癌症阻断治疗提供了新的契机。

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-012066
Chen, Xinyuan; Sun, Shanyue; Li, Shuofeng; Yu, Shuangni; Chen, Jie; Chen, Xianlong
细胞生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study

免疫检查点抑制剂联合治疗后行转化手术治疗初始不可切除的肝细胞癌：一项回顾性队列研究

期刊:Liver Cancer
影响因子:9.1
doi:10.1159/000543994
Piao, Mingjian; Li, Chengjie; Huang, Ziyue; Zhang, Nan; Li, Jiongyuan; Yang, Xu; Li, Shuofeng; Wang, Shanshan; Xun, Ziyu; Zhang, Longhao; Sun, Boyu; Zhang, Ting; Yang, Xiaobo; Zhao, Haitao
Checkpoint
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis

单细胞转录组分析揭示了免疫相关性心肌炎中以CXCL9+成纤维细胞和ACKR1+内皮细胞为特征的炎症微环境

期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/s12967-025-06551-x
Sun, Boyu; Xun, Ziyu; Zhou, Zixiang; Zhang, Nan; Piao, Mingjian; Li, Chengjie; Li, Jiongyuan; Li, Shuofeng; Zhang, Longhao; Chen, Xiangqi; Wang, Hanping; Zhao, Haitao
CXCL9
成纤维细胞
炎症
单细胞
心肌炎
炎症/感染
心血管
内皮细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study

局部区域治疗联合化疗、免疫检查点抑制剂和乐伐替尼一线治疗晚期肝内胆管癌的疗效和安全性：一项多中心回顾性队列研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04085-1
Li, Shuofeng; Yu, Guanhua; Wang, Mingming; Feng, Shi; Wang, Shanshan; Piao, Mingjian; Li, Chengjie; Zhou, Zixiang; Xun, Ziyu; Sun, Boyu; Li, Jiongyuan; Zhang, Nan; Li, Hu; Yang, Xiaobo; Zhu, Zhenyu; Zhao, Haitao
免疫/内分泌
胆管癌
肿瘤免疫
肿瘤
发表日期：2025
文献求助 收藏

Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma

局部治疗克服了不可切除肝细胞癌对靶向免疫疗法联合治疗的原发性耐药性

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04184-z
Chen, Xiangqi; Piao, Mingjian; Zhou, Zixiang; Wang, Shanshan; Li, Shuofeng; Zhang, Nan; Sun, Boyu; Liu, Kai; Yang, Xu; Yang, Xiaobo; Shi, Xiaohua; Zhu, Chengpei; Zhao, Haitao
免疫/内分泌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study

局部区域治疗联合免疫检查点抑制剂和乐伐替尼与免疫检查点抑制剂联合化疗治疗晚期肝内胆管癌的疗效比较：一项多中心队列研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04129-6
Li, Shuofeng; Yu, Guanhua; Wang, Mingming; Feng, Shi; Zhang, An; Wu, Yu; Zhou, Zixiang; Wang, Shanshan; Zhang, Yihong; Piao, Mingjian; Li, Chengjie; Xun, Ziyu; Sun, Boyu; Li, Jiongyuan; Zhang, Nan; Li, Hu; Sun, Yongliang; Zhang, Wen; Zhu, Zhenyu; Zhao, Haitao
免疫/内分泌
胆管癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer

免疫疗法的改变克服了不可切除胆道癌化疗-免疫疗法后产生的耐药性

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04181-2
Chen, Xiangqi; Zhou, Zixiang; Li, Shuofeng; Yu, Guanhua; Feng, Shi; Zhou, Ze; Sun, Boyu; Wang, Shanshan; Liu, Kai; Li, Chengjie; Piao, Mingjian; Wang, Mingming; Zhang, Yihong; Li, Hu; Zhu, Chengpei; Zhu, Zhenyu; Zhao, Haitao
肿瘤
胆管癌
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏